MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

CureVac NV

Geschlossen

5.39

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.39

Max

5.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.3M

-60M

Verkäufe

352K

1.2M

KGV

Branchendurchschnitt

5.297

35.739

Gewinnspanne

-4,816.546

Angestellte

825

EBITDA

-8.2M

-55M

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-18M

1.2B

Vorheriger Eröffnungskurs

5.39

Vorheriger Schlusskurs

5.39

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

CureVac NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Juni 2025, 14:20 UTC

Akquisitionen, Fusionen, Übernahmen

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12. Juni 2025, 13:34 UTC

Heiße Aktien

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Peer-Vergleich

Kursveränderung

CureVac NV Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

3.47 / 3.755Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
help-icon Live chat